Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...

Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...

Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework Observational studies or ...

Leronlimab increases PD-L1 expression on circulating tumor cells, potentially converting "cold" tumors to "hot" ones, enhancing immune response in metastatic triple-negative breast cancer. In a study, ...

PARSIPPANY, NJ--(Marketwired - Feb 3, 2016) - Diaceutics Group, a dedicated integrator in personalized and precision medicine, enabling the effective combination of therapies and diagnostics into the ...

PD-L1の発現が90％以上の進行非小細胞肺癌（NSCLC）患者の1次治療として、抗PD-1抗体セミプリマブまたはペムブロリズマブの単剤療法が良好な全生存期間（OS）と無増悪生存期間（PFS）を示すことが、3年の観察期間でも認められることが分かった。2つの独立し ...

Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...

抗PD-1/PD-L1抗体を含む治療歴がある固形癌患者に対して、T細胞受容体β鎖を標的としたデュアルT細胞アゴニストのinvikafusp ...

New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...

VANCOUVER, Washington, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized ...